# NEOGENOMICS INC

Summary updated: 2026-10-02T12:23:07.382873Z
Canonical: https://finbar.com/research/companies/neogenomics-inc

## Overview

NeoGenomics, Inc. is a cancer-focused diagnostics company providing laboratory testing and consultative services to clinicians and biopharmaceutical companies. Its offerings include molecular and next-generation sequencing tests, minimal residual disease testing, and services supporting pharmaceutical development. The company’s stated mission is “to save lives by improving patient care.” [1](https://app.finbar.com/go?id=P101484624)[2](https://app.finbar.com/go?id=P97443716)[3](https://app.finbar.com/go?id=P102390047)[4](https://app.finbar.com/go?id=P35265616)

The company operates cancer-testing laboratories in the United States and the United Kingdom, including a sample-processing laboratory in Cambridge, UK. For FY2025, NeoGenomics reported revenue of $727 million and 2,500 employees as of December 31, 2025. Its latest reported interim results are for Q2 2026, with revenue of $201.7 million for the quarter. [5](https://app.finbar.com/go?id=P10847323)[6](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm)[7](https://ir.neogenomics.com/news-events/press-releases/detail/320/neogenomics-reports-fourth-quarter-and-full-year-2025-results)[8](https://app.finbar.com/go?id=T16470168)
[1](https://app.finbar.com/go?id=P101484624)[2](https://app.finbar.com/go?id=P97443716)[3](https://app.finbar.com/go?id=P102390047)[4](https://app.finbar.com/go?id=P35265616)[5](https://app.finbar.com/go?id=P10847323)[8](https://app.finbar.com/go?id=T16470168)[6](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm)[7](https://ir.neogenomics.com/news-events/press-releases/detail/320/neogenomics-reports-fourth-quarter-and-full-year-2025-results)

## Products & services

NeoGenomics offers oncology diagnostic testing that includes cytogenetics and karyotyping, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC), digital imaging, molecular testing and minimal residual disease (MRD) testing. FISH detects and localizes targeted DNA sequences and can identify chromosome amplifications, deletions and translocations; flow cytometry characterizes cells using fluorescent antibodies. Its digital imaging service allows clients to view scanned slides online. [9](https://app.finbar.com/go?id=P99107339)[10](https://app.finbar.com/go?id=P50208718)[11](https://app.finbar.com/go?id=P118049826)[12](https://app.finbar.com/go?id=P88871012)

Its named molecular testing offerings include the PanTracer portfolio (PanTracer Tissue, PanTracer Tissue + HRD and PanTracer LBx), Neo Comprehensive panels for hematologic cancers and myeloid disorders, and cancer-specific NeoTYPE panels. PanTracer LBx uses a blood sample and a 514-gene next-generation sequencing panel to report sequence variants, insertions and deletions, copy-number variants and fusions, as well as microsatellite instability and blood tumor mutational burden. The company also provides single-gene testing and whole-exome sequencing for pharmaceutical development services. [13](https://app.finbar.com/go?id=P9720088)[3](https://app.finbar.com/go?id=P102390047)[14](https://neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pantracer-lbx)[15](https://app.finbar.com/go?id=P48988069)

RaDaR and RaDaR ST are plasma-based liquid-biopsy MRD tests for solid tumors. RaDaR ST uses tumor-tissue whole-exome sequencing to create a personalized assay that tracks up to 48 variants in serial plasma samples using PCR and next-generation sequencing. Other offerings include NeoLAB pathology services—such as test-selection and workflow consulting, laboratory internalization support and quality assurance—and oncology data solutions including NeoEngage, NeoPixel, NeoAccelerate and NeoExplore. [16](https://app.finbar.com/go?id=P114291845)[17](https://neogenomics.com/providers/test/MOG-RDFX-01BZ/radar-st)[18](https://www.neogenomics.com/diagnostic-services/specialty-testing/neolab)[19](https://neogenomics.com/informatics-data-solutions)
[9](https://app.finbar.com/go?id=P99107339)[10](https://app.finbar.com/go?id=P50208718)[11](https://app.finbar.com/go?id=P118049826)[12](https://app.finbar.com/go?id=P88871012)[13](https://app.finbar.com/go?id=P9720088)[3](https://app.finbar.com/go?id=P102390047)[15](https://app.finbar.com/go?id=P48988069)[16](https://app.finbar.com/go?id=P114291845)[14](https://neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pantracer-lbx)[17](https://neogenomics.com/providers/test/MOG-RDFX-01BZ/radar-st)[18](https://www.neogenomics.com/diagnostic-services/specialty-testing/neolab)[19](https://neogenomics.com/informatics-data-solutions)

## Geographic presence

NeoGenomics serves clients throughout the United States and the United Kingdom. Its clinical-services sales force is organized into ten U.S. regions: Northeast, Pacific North, South Central, South East, West, Mid-Atlantic, Mountain, Central, Great Lakes, and Florida. [20](https://app.finbar.com/go?id=P61872491)[21](https://app.finbar.com/go?id=P81230055) The 2025 annual filing identifies U.S. and U.K. markets but does not provide revenue by country or region. [20](https://app.finbar.com/go?id=P61872491)[6](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm)

Its full-service laboratories are located in Fort Myers, Aliso Viejo, Carlsbad, Durham, Ramsey, and Houston, with a full-service sample-processing laboratory in Cambridge, United Kingdom. The filing also lists facilities in Nashville, Tampa, Phoenix, Fresno, Chicago, Plantation, and Sarasota, in addition to those full-service lab locations. [5](https://app.finbar.com/go?id=P10847323)[22](https://app.finbar.com/go?id=T12790567) The company’s principal executive offices are in Fort Myers, Florida. [23](https://app.finbar.com/go?id=P143937705)
[20](https://app.finbar.com/go?id=P61872491)[21](https://app.finbar.com/go?id=P81230055)[5](https://app.finbar.com/go?id=P10847323)[22](https://app.finbar.com/go?id=T12790567)[23](https://app.finbar.com/go?id=P143937705)[6](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm)

## Business segments

NeoGenomics reports one operating and reportable segment, rather than separate clinical and pharmaceutical-services segments. Its FY2025 segment revenue was $727.3 million, representing 100% of reported segment revenue and consolidated revenue. The company’s Q2 2026 filing continued to describe it as a single-segment business. [24](https://app.finbar.com/go?id=P28811732)[25](https://app.finbar.com/go?id=P99140443)[26](https://app.finbar.com/go?id=T11677654)[27](https://app.finbar.com/go?id=P143937978)

Within that segment, the company provides oncology diagnostic testing and related interpretation and consultative services, including hematologic and solid-tumor testing and molecular diagnostics. It also supports pharmaceutical and biotechnology customers with laboratory testing, biomarker analysis, assay development, and clinical-trial and research services. These activities are not reported as separate segments, and the filings do not provide revenue percentages for them. [1](https://app.finbar.com/go?id=P101484624)[13](https://app.finbar.com/go?id=P9720088)[16](https://app.finbar.com/go?id=P114291845)[28](https://app.finbar.com/go?id=P29476527)[29](https://app.finbar.com/go?id=P56969070)[24](https://app.finbar.com/go?id=P28811732)

The FY2025 filing states that substantially all revenue and tangible long-lived assets are attributable to the United States, but does not give a precise geographic revenue percentage. [30](https://app.finbar.com/go?id=P51104568)
[24](https://app.finbar.com/go?id=P28811732)[25](https://app.finbar.com/go?id=P99140443)[26](https://app.finbar.com/go?id=T11677654)[27](https://app.finbar.com/go?id=P143937978)[1](https://app.finbar.com/go?id=P101484624)[13](https://app.finbar.com/go?id=P9720088)[16](https://app.finbar.com/go?id=P114291845)[28](https://app.finbar.com/go?id=P29476527)[29](https://app.finbar.com/go?id=P56969070)[30](https://app.finbar.com/go?id=P51104568)

## Company history

NeoGenomics traces its beginnings to 1999; it was incorporated on June 1, 2001, with Dr. Michael T. Dent identified as its founder, and became a publicly traded company later that year. [31](https://neogenomics.com/about-neogenomics/?page=1)[32](https://ir.neogenomics.com/company-information/faq)[33](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001193125-15-161819/0001193125-15-161819.pdf) By 2015, the company had developed more than 125 molecular oncology tests and disease-specific panels. [34](https://app.finbar.com/go?id=P190028015) It expanded through the 2014 acquisition of Path Logic and the 2015 acquisition of Clarient, which significantly increased its scale and oncology-testing capabilities. [35](https://app.finbar.com/go?id=P190028666)[36](https://ir.neogenomics.com/news-events/press-releases/detail/29/neogenomics-completes-acquisition-of-path-logic)[37](https://ir.neogenomics.com/news-events/press-releases/detail/59/neogenomics-completes-acquisition-of-clarient-inc)

In 2017, NeoGenomics opened its first international laboratory, in Rolle, Switzerland, to support clinical trials and pharmaceutical services in Europe. [38](https://ir.neogenomics.com/news-events/press-releases/detail/82/neogenomics-announces-the-opening-of-its-first-international-laboratory-near-geneva-switzerland-to-support-clinical-trials)[39](https://ir.neogenomics.com/news-events/press-releases/detail/84/neogenomics-europe-s-a-opens-its-doors-in-rolle-switzerland-laboratory-hosting-business-leaders-dignitaries-and-local-government-officials) It acquired Genoptix in December 2018, broadening its clinical oncology diagnostics business. [40](https://app.finbar.com/go?id=P184038188)[41](https://ir.neogenomics.com/news-events/press-releases/detail/105/neogenomics-completes-acquisition-of-genoptix-inc)

In 2021, the company acquired Trapelo Health, a precision-oncology decision-support business, and completed its acquisition of Inivata, adding liquid-biopsy technology and capabilities. [42](https://app.finbar.com/go?id=P118206759)[43](https://app.finbar.com/go?id=P65777980)[44](https://ir.neogenomics.com/news-events/press-releases/detail/180/neogenomics-completes-inivata-acquisition---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform) CEO succession followed: Mark Mallon took over from Douglas VanOort in April 2021, Chris Smith became CEO in 2022, and Tony Zook succeeded Smith in April 2025. [45](https://ir.neogenomics.com/news-events/press-releases/detail/167/neogenomics-announces-ceo-succession)[46](https://app.finbar.com/go?id=P29071888)[47](https://ir.neogenomics.com/news-events/press-releases/detail/284/neogenomics-announces-chief-executive-officer-succession)
[34](https://app.finbar.com/go?id=P190028015)[35](https://app.finbar.com/go?id=P190028666)[40](https://app.finbar.com/go?id=P184038188)[42](https://app.finbar.com/go?id=P118206759)[43](https://app.finbar.com/go?id=P65777980)[46](https://app.finbar.com/go?id=P29071888)[31](https://neogenomics.com/about-neogenomics/?page=1)[32](https://ir.neogenomics.com/company-information/faq)[33](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001193125-15-161819/0001193125-15-161819.pdf)[36](https://ir.neogenomics.com/news-events/press-releases/detail/29/neogenomics-completes-acquisition-of-path-logic)[37](https://ir.neogenomics.com/news-events/press-releases/detail/59/neogenomics-completes-acquisition-of-clarient-inc)[38](https://ir.neogenomics.com/news-events/press-releases/detail/82/neogenomics-announces-the-opening-of-its-first-international-laboratory-near-geneva-switzerland-to-support-clinical-trials)[39](https://ir.neogenomics.com/news-events/press-releases/detail/84/neogenomics-europe-s-a-opens-its-doors-in-rolle-switzerland-laboratory-hosting-business-leaders-dignitaries-and-local-government-officials)[41](https://ir.neogenomics.com/news-events/press-releases/detail/105/neogenomics-completes-acquisition-of-genoptix-inc)[44](https://ir.neogenomics.com/news-events/press-releases/detail/180/neogenomics-completes-inivata-acquisition---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform)[45](https://ir.neogenomics.com/news-events/press-releases/detail/167/neogenomics-announces-ceo-succession)[47](https://ir.neogenomics.com/news-events/press-releases/detail/284/neogenomics-announces-chief-executive-officer-succession)

## Sources

1. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P101484624)
2. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97443716)
3. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P102390047)
4. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P35265616)
5. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P10847323)
6. [ir.neogenomics.com](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm)
7. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/320/neogenomics-reports-fourth-quarter-and-full-year-2025-results)
8. [NEOGENOMICS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16470168)
9. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P99107339)
10. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P50208718)
11. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P118049826)
12. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P88871012)
13. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P9720088)
14. [neogenomics.com](https://neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pantracer-lbx)
15. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P48988069)
16. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P114291845)
17. [neogenomics.com](https://neogenomics.com/providers/test/MOG-RDFX-01BZ/radar-st)
18. [www.neogenomics.com](https://www.neogenomics.com/diagnostic-services/specialty-testing/neolab)
19. [neogenomics.com](https://neogenomics.com/informatics-data-solutions)
20. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P61872491)
21. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P81230055)
22. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T12790567)
23. [NEOGENOMICS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143937705)
24. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P28811732)
25. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P99140443)
26. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T11677654)
27. [NEOGENOMICS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143937978)
28. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29476527)
29. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P56969070)
30. [NEOGENOMICS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P51104568)
31. [neogenomics.com](https://neogenomics.com/about-neogenomics/?page=1)
32. [ir.neogenomics.com](https://ir.neogenomics.com/company-information/faq)
33. [ir.neogenomics.com](https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001193125-15-161819/0001193125-15-161819.pdf)
34. [NEOGENOMICS INC — Full financial report (2015 Y)](https://app.finbar.com/go?id=P190028015)
35. [NEOGENOMICS INC — Full financial report (2015 Y)](https://app.finbar.com/go?id=P190028666)
36. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/29/neogenomics-completes-acquisition-of-path-logic)
37. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/59/neogenomics-completes-acquisition-of-clarient-inc)
38. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/82/neogenomics-announces-the-opening-of-its-first-international-laboratory-near-geneva-switzerland-to-support-clinical-trials)
39. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/84/neogenomics-europe-s-a-opens-its-doors-in-rolle-switzerland-laboratory-hosting-business-leaders-dignitaries-and-local-government-officials)
40. [NEOGENOMICS INC — Full financial report (2018 Y)](https://app.finbar.com/go?id=P184038188)
41. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/105/neogenomics-completes-acquisition-of-genoptix-inc)
42. [NEOGENOMICS INC — Full financial report (2021 Y)](https://app.finbar.com/go?id=P118206759)
43. [NEOGENOMICS INC — Full financial report (2021 Y)](https://app.finbar.com/go?id=P65777980)
44. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/180/neogenomics-completes-inivata-acquisition---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform)
45. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/167/neogenomics-announces-ceo-succession)
46. [NEOGENOMICS INC — Transcript (2022 Q 2)](https://app.finbar.com/go?id=P29071888)
47. [ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/284/neogenomics-announces-chief-executive-officer-succession)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.